Usage of different lots of RLDs in multistage adaptive studies [Regulatives / Guidelines]

posted by ElMaestro  – Denmark, 2018-09-20 14:19 (1650 d 17:41 ago) – Posting: # 19294
Views: 1,635

Hi manusyriac,

❝ Can we use different lots of RLDS in multistage studies as the study design requires more than 2 years of shelf-life for RLDs. If it is possible please help me to find any relevant regulatory guidance for the same.


Without being absolutely sure I think this would be ok with most EU authorities for the reasons you state. Less convinced about how HC or FDA or PMDA would see it.
Note that in your case batch and stage will have the same meaning for the product(s) in question.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
22,557 posts in 4,724 threads, 1,607 registered users;
21 visitors (0 registered, 21 guests [including 11 identified bots]).
Forum time: 08:01 CEST (Europe/Vienna)

The function of genius is not to give new answers, but to pose
new questions which time and mediocrity can resolve.    H.R. Trevor-Roper

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5